NCT05947890: Evaluating the Safety and Immunogenicity of MTBVAC
- State
- Under way
- Phase
- Phase 2
- People
- 276 planned
- Started
- 30 Jan 2024
- Primary completion
- Nov 2027
- Arms
- 1.1b - Adolescents and adults without HIV and negative interferon-gamma release assay, 1.2b - Adolescents and adults without HIV and positive interferon-gamma release assay, 2.1.b - Adolescents and adults with well-controlled HIV and negative interferon-gamma release assay, 2.2 b- Adolescents and adults with well-controlled HIV and positive interferon-gamma release assay, 3.1 b- Adults with well-controlled HIV and negative interferon-gamma release assay, 3.2 b- Adults with well-controlled HIV and positive interferon-gamma release assay
- Results
- None posted
- 17 Jul 2023: Trial registered
- 30 Jan 2024: Trial started